

William Hogan

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5191791/publications.pdf>

Version: 2024-02-01

338
papers

5,616
citations

94269

37
h-index

110170

64
g-index

339
all docs

339
docs citations

339
times ranked

6604
citing authors

| # | ARTICLE | IF | CITATIONS |
|----|--|-----|-----------|
| 1 | Use of sublingual tacrolimus in adults undergoing hematopoietic cell transplant: A pilot study. <i>Journal of Oncology Pharmacy Practice</i> , 2022, 28, 387-394. | 0.5 | 0 |
| 2 | Comparative study of therapy-related and de novo adult B-cell acute lymphoblastic leukaemia. <i>British Journal of Haematology</i> , 2022, 196, 963-968. | 1.2 | 6 |
| 3 | European LeukemiaNet-defined primary refractory acute myeloid leukemia: the value of allogeneic hematopoietic stem cell transplant and overall response. <i>Blood Cancer Journal</i> , 2022, 12, 7. | 2.8 | 5 |
| 4 | Cardiac events in patients with acute myeloid leukemia treated with venetoclax combined with hypomethylating agents. <i>Blood Advances</i> , 2022, 6, 5227-5231. | 2.5 | 5 |
| 5 | Real-world experience with venetoclax and hypomethylating agents in myelodysplastic syndromes with excess blasts. <i>American Journal of Hematology</i> , 2022, 97, . | 2.0 | 10 |
| 6 | Real-world experience with luspatercept and predictors of response in myelodysplastic syndromes with ring sideroblasts. <i>American Journal of Hematology</i> , 2022, 97, . | 2.0 | 13 |
| 7 | Impact of maintenance therapy post autologous stem cell transplantation for multiple myeloma in early and delayed transplant. <i>Bone Marrow Transplantation</i> , 2022, 57, 803-809. | 1.3 | 6 |
| 8 | Core-binding factor acute myeloid leukemia: long-term outcome of 70 patients uniformly treated with 7+3. <i>Blood Cancer Journal</i> , 2022, 12, 55. | 2.8 | 4 |
| 9 | Success of the autologous stem cell boost after autologous graft failure in multiple myeloma and AL amyloidosis. <i>Bone Marrow Transplantation</i> , 2022, , . | 1.3 | 0 |
| 10 | Impact of Center Experience with Donor Type on Outcomes: A Secondary Analysis, Blood and Marrow Transplant Clinical Trials Network 1101. <i>Bone Marrow Transplantation and Cellular Therapy</i> , 2022, 28, 406.e1-406.e6. | 0.6 | 4 |
| 11 | Treatment and outcomes of patients with light chain amyloidosis who received a second line of therapy post autologous stem cell transplantation. <i>Blood Cancer Journal</i> , 2022, 12, 59. | 2.8 | 3 |
| 12 | Assessment of systemic and gastrointestinal tissue damage biomarkers for GVHD risk stratification. <i>Blood Advances</i> , 2022, 6, 3707-3715. | 2.5 | 9 |
| 13 | Lack of a caregiver is associated with shorter survival in myeloma patients undergoing autologous stem cell transplantation. <i>Leukemia and Lymphoma</i> , 2022, 63, 2422-2427. | 0.6 | 2 |
| 14 | Relationship of iothalamate clearance and NRM in patients receiving fludarabine and melphalan reduced-intensity conditioning. <i>Blood Advances</i> , 2022, , . | 2.5 | 1 |
| 15 | Limited activity of fedratinib in myelofibrosis patients relapsed/refractory to ruxolitinib 20mg twice daily or higher: A real-world experience. <i>British Journal of Haematology</i> , 2022, 198, . | 1.2 | 7 |
| 16 | Therapy-related clonal cytopenia as a precursor to therapy-related myeloid neoplasms. <i>Blood Cancer Journal</i> , 2022, 12, . | 2.8 | 7 |
| 17 | Prognostic value of NT-ProBNP and troponin T in patients with light chain amyloidosis and kidney dysfunction undergoing autologous stem cell transplantation. <i>Bone Marrow Transplantation</i> , 2021, 56, 274-277. | 1.3 | 1 |
| 18 | Cardiovascular outcomes in patients receiving myeloablative vs. reduced intensity conditioning prior to allogeneic hematopoietic stem cell transplantation for acute myeloid leukemia. <i>Bone Marrow Transplantation</i> , 2021, 56, 508-510. | 1.3 | 0 |

| # | ARTICLE | IF | CITATIONS |
|----|---|-----|-----------|
| 19 | Leukocytosis and Tobacco Use: An Observational Study of Asymptomatic Leukocytosis. American Journal of Medicine, 2021, 134, e31-e35. | 0.6 | 13 |
| 20 | Autologous stem cell transplantation for multiple myeloma patients aged ≥ 75 treated with novel agents. Bone Marrow Transplantation, 2021, 56, 1144-1150. | 1.3 | 15 |
| 21 | Impact of Novel Targeted Therapies and Cytogenetic Risk Groups on Outcome After Allogeneic Transplantation for Adult ALL. Transplantation and Cellular Therapy, 2021, 27, 165.e1-165.e11. | 0.6 | 11 |
| 22 | Use of autologous stem cells cryopreserved for over 15 years in stem cell transplantation for multiple myeloma. Bone Marrow Transplantation, 2021, 56, 978-979. | 1.3 | 0 |
| 23 | Depth of response prior to autologous stem cell transplantation predicts survival in light chain amyloidosis. Bone Marrow Transplantation, 2021, 56, 928-935. | 1.3 | 5 |
| 24 | Risk of relapse in patients receiving azithromycin after allogeneic HSCT. Bone Marrow Transplantation, 2021, 56, 960-962. | 1.3 | 3 |
| 25 | Chronic graft-versus-host disease in pancreas after kidney transplant recipients – An unrecognized entity. American Journal of Transplantation, 2021, 21, 883-888. | 2.6 | 2 |
| 26 | PD-1/PD-L1 expression in extramedullary lesions of acute myeloid leukemia. Leukemia and Lymphoma, 2021, 62, 764-767. | 0.6 | 7 |
| 27 | The Impact of Obesity on the Outcomes of Adult Patients with Acute Lymphoblastic Leukemia – A Single Center Retrospective Study. Blood and Lymphatic Cancer: Targets and Therapy, 2021, Volume 11, 1-9. | 1.2 | 8 |
| 28 | Salvage use of venetoclax-based therapy for relapsed AML post allogeneic hematopoietic cell transplantation. Blood Cancer Journal, 2021, 11, 49. | 2.8 | 28 |
| 29 | Hypomagnesemia at the time of autologous stem cell transplantation for patients with diffuse large B-cell lymphoma is associated with an increased risk of failure. Blood Cancer Journal, 2021, 11, 65. | 2.8 | 3 |
| 30 | Acute myeloid leukemia after age 70 years: A retrospective comparison of survival following treatment with intensive versus HMA ± venetoclax chemotherapy. American Journal of Hematology, 2021, 96, E108-E111. | 2.0 | 7 |
| 31 | Mayo Clinic experience with 1123 adults with acute myeloid leukemia. Blood Cancer Journal, 2021, 11, 46. | 2.8 | 6 |
| 32 | D-dimer as a marker of bloodstream infections in patients with allogeneic hematopoietic stem cell transplantation. Transplant Infectious Disease, 2021, 23, e13588. | 0.7 | 0 |
| 33 | Characteristics and outcomes of therapy-related myeloid neoplasms following autologous stem cell transplantation for multiple myeloma. Blood Cancer Journal, 2021, 11, 63. | 2.8 | 11 |
| 34 | Clinical and biological characteristics and prognostic impact of somatic GATA2 mutations in myeloid malignancies: a single institution experience. Blood Cancer Journal, 2021, 11, 122. | 2.8 | 7 |
| 35 | Epidemiology, Risk Factors, and Outcomes of Diffuse Alveolar Hemorrhage After Hematopoietic Stem Cell Transplantation. Chest, 2021, 159, 2325-2333. | 0.4 | 11 |
| 36 | Clinical features and survival outcomes in patients with chronic myelomonocytic leukemia arising in the context of germline predisposition syndromes. American Journal of Hematology, 2021, 96, E327-E330. | 2.0 | 6 |

| # | ARTICLE | IF | CITATIONS |
|----|--|-----|-----------|
| 37 | Ruxolitinib resistance or intolerance in steroidâ€refractory acute graftâ€versus â€host disease â€” a realâ€world outcomes analysis. <i>British Journal of Haematology</i> , 2021, 195, 429-432. | 1.2 | 6 |
| 38 | Second Stem Cell Transplantation for Relapsed Refractory Light Chain (AL) Amyloidosis. <i>Transplantation and Cellular Therapy</i> , 2021, 27, 589.e1-589.e6. | 0.6 | 3 |
| 39 | Evaluation of Elafin as a Prognostic Biomarker in Acute Graft-versus-Host Disease. <i>Transplantation and Cellular Therapy</i> , 2021, 27, 988.e1-988.e7. | 0.6 | 10 |
| 40 | <i>De novo</i> isolated myeloid sarcoma: comparative analysis of survival in 19 consecutive cases. <i>British Journal of Haematology</i> , 2021, 195, 413-416. | 1.2 | 9 |
| 41 | Hemoglobinuria in the early post stem cell transplant period: Risk factors and association with outcomes. <i>Kidney360</i> , 2021, 2, 10.34067/KID.0002262021. | 0.9 | 0 |
| 42 | Spectrum of hematological malignancies, clonal evolution and outcomes in 144 Mayo Clinic patients with germline predisposition syndromes. <i>American Journal of Hematology</i> , 2021, 96, 1450-1460. | 2.0 | 19 |
| 43 | An adapted European LeukemiaNet genetic risk stratification for acute myeloid leukemia patients undergoing allogeneic hematopoietic cell transplant. A CIBMTR analysis. <i>Bone Marrow Transplantation</i> , 2021, 56, 3068-3077. | 1.3 | 13 |
| 44 | Identification of adult Philadelphia-like acute lymphoblastic leukemia using a FISHâ€based algorithm distinguishes prognostic groups and outcomes. <i>Blood Cancer Journal</i> , 2021, 11, 156. | 2.8 | 4 |
| 45 | Outcomes of venetoclaxâ€based therapy in chronic phase and blast transformed chronic myelomonocytic leukemia. <i>American Journal of Hematology</i> , 2021, 96, E433-E436. | 2.0 | 10 |
| 46 | The Efficacy and Safety of Chemotherapy-Based Stem Cell Mobilization in Multiple Myeloma Patients Who Are Poor Responders to Induction: The Mayo Clinic Experience. <i>Transplantation and Cellular Therapy</i> , 2021, 27, 770.e1-770.e7. | 0.6 | 6 |
| 47 | <scp>Pseudoâ€Vollmann</scp> contracture as a complication of chronic graftâ€versusâ€host disease. <i>Dermatologic Therapy</i> , 2021, 34, e14701. | 0.8 | 2 |
| 48 | Clinical and molecular correlates from a predominantly adult cohort of patients with short telomere lengths. <i>Blood Cancer Journal</i> , 2021, 11, 170. | 2.8 | 6 |
| 49 | Anthracycline Choices for Induction Chemotherapy Among 797 Consecutive Adult Patients with Acute Myeloid Leukemia: Daunorubicin-60 Vs Idarubicin-12 Vs Daunorubicin-90. <i>Blood</i> , 2021, 138, 1267-1267. | 0.6 | 0 |
| 50 | A novel Iowaâ€Mayo validated composite risk assessment tool for allogeneic stem cell transplantation survival outcome prediction. <i>Blood Cancer Journal</i> , 2021, 11, 183. | 2.8 | 0 |
| 51 | Prognostic Value of Elafin in Acute Graft-Versus-Host Disease. <i>Blood</i> , 2021, 138, 3900-3900. | 0.6 | 0 |
| 52 | Therapy-Related Cytopenia of Undetermined Significance (t-CCUS) As a Precursor to Therapy-Related Myeloid Neoplasms (t-MN). <i>Blood</i> , 2021, 138, 1096-1096. | 0.6 | 0 |
| 53 | Acute Myeloid Leukemia in the Context of Previous History of Cancer with or without Exposure to Chemotherapy or Radiotherapy. <i>Blood</i> , 2021, 138, 3368-3368. | 0.6 | 1 |
| 54 | Impact of Center Experience with Donor Type and Treatment Platform on Outcomes: A Secondary Analysis BMT CTN 1101. <i>Blood</i> , 2021, 138, 3956-3956. | 0.6 | 0 |

| # | ARTICLE | IF | CITATIONS |
|----|---|-----|-----------|
| 55 | T-MDS Is a Distinct Clinical and Pathological Entity Characterized By Better Survival Compared to t-AML. <i>Blood</i> , 2021, 138, 3377-3377. | 0.6 | 0 |
| 56 | The D-index is not correlated with invasive fungal infection during the early-post engraftment phase among allogeneic hematopoietic stem cell transplant recipients. <i>International Journal of Hematology</i> , 2020, 111, 293-302. | 0.7 | 4 |
| 57 | Delayed neutrophil engraftment in patients receiving Daratumumab as part of their first induction regimen for multiple myeloma. <i>American Journal of Hematology</i> , 2020, 95, E8-E10. | 2.0 | 10 |
| 58 | Clinical utility of fluorescence in situ hybridization-based diagnosis of <i>BCR-ABL1</i> like (<sc>P</sc>hiladelphia chromosome like) <sc>B</sc>-acute lymphoblastic leukemia. <i>American Journal of Hematology</i> , 2020, 95, E68-E72. | 2.0 | 4 |
| 59 | Systemic methotrexate absorption in a patient receiving intrathecal chemotherapy for acute lymphoblastic leukemia. <i>Leukemia and Lymphoma</i> , 2020, 61, 993-995. | 0.6 | 2 |
| 60 | Emergencies in haematology: tumour lysis syndrome. <i>British Journal of Haematology</i> , 2020, 188, 494-500. | 1.2 | 15 |
| 61 | Prognostic impact and timing considerations for allogeneic hematopoietic stem cell transplantation in chronic myelomonocytic leukemia. <i>Blood Cancer Journal</i> , 2020, 10, 121. | 2.8 | 21 |
| 62 | Venetoclax and hypomethylating agents in acute myeloid leukemia: Mayo Clinic series on 86 patients. <i>American Journal of Hematology</i> , 2020, 95, 1511-1521. | 2.0 | 83 |
| 63 | Differences in engraftment with day-1 compared with day-2 melphalan prior to stem cell infusion in myeloma patients receiving autologous stem cell transplant. <i>Bone Marrow Transplantation</i> , 2020, 55, 2132-2137. | 1.3 | 8 |
| 64 | Composite GRFS and CRFS Outcomes After Adult Alternative Donor HCT. <i>Journal of Clinical Oncology</i> , 2020, 38, 2062-2076. | 0.8 | 36 |
| 65 | Prognostic Role of Beta-2 Microglobulin in Patients with Light Chain Amyloidosis Treated with Autologous Stem Cell Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2020, 26, 1402-1405. | 2.0 | 4 |
| 66 | A population-based study of chronic neutrophilic leukemia in the United States. <i>Blood Cancer Journal</i> , 2020, 10, 68. | 2.8 | 8 |
| 67 | Outcomes with early vs. deferred stem cell transplantation in light chain amyloidosis. <i>Bone Marrow Transplantation</i> , 2020, 55, 1297-1304. | 1.3 | 5 |
| 68 | Early post-transplantation factors predict survival outcomes in patients undergoing allogeneic hematopoietic cell transplantation for myelofibrosis. <i>Blood Cancer Journal</i> , 2020, 10, 36. | 2.8 | 14 |
| 69 | Characteristics of patients with myelodysplastic syndrome with balanced translocations. <i>British Journal of Haematology</i> , 2020, 190, 244-248. | 1.2 | 1 |
| 70 | Clinical outcomes of adults with hemophagocytic lymphohistiocytosis treated with the HLH-04 protocol: a retrospective analysis. <i>Leukemia and Lymphoma</i> , 2020, 61, 1592-1600. | 0.6 | 17 |
| 71 | Baseline immune dysregulation in autologous stem cell transplant recipients is associated with a "graft versus host"-like syndrome and poor outcomes. <i>Bone Marrow Transplantation</i> , 2020, 55, 1879-1881. | 1.3 | 1 |
| 72 | Response to erythropoiesis-stimulating agents in patients with WHO-defined myelodysplastic syndrome/myeloproliferative neoplasm with ring sideroblasts and thrombocytosis (MDS/MPN<sc>RS</sc>). <i>British Journal of Haematology</i> , 2020, 189, e104-e108. | 1.2 | 8 |

| # | ARTICLE | IF | CITATIONS |
|----|---|-----|-----------|
| 73 | A population-based study of chronic eosinophilic <scp>leukemia¬</scp> otherwise specified in the United States. American Journal of Hematology, 2020, 95, E257. | 2.0 | 6 |
| 74 | Characteristics of late transplant-associated thrombotic microangiopathy in patients who underwent allogeneic hematopoietic stem cell transplantation. American Journal of Hematology, 2020, 95, 1170-1179. | 2.0 | 19 |
| 75 | Impact of marrow blasts percentage on high-grade myelodysplastic syndrome assessed using revised international prognostic scoring system. Annals of Hematology, 2020, 99, 513-518. | 0.8 | 1 |
| 76 | Disease risk and GVHD biomarkers can stratify patients for risk of relapse and nonrelapse mortality post hematopoietic cell transplant. Leukemia, 2020, 34, 1898-1906. | 3.3 | 16 |
| 77 | Risk Factors for Keratinocyte Carcinoma in Recipients of Allogeneic Hematopoietic Cell Transplants. JAMA Dermatology, 2020, 156, 631. | 2.0 | 9 |
| 78 | Presence of a Measurable M-Spike before Autologous Stem Cell Transplantation Is Associated with Shorter Survival in Patients with Light Chain Amyloidosis. Blood, 2020, 136, 22-23. | 0.6 | 1 |
| 79 | Biomarker-guided preemption of steroid-refractory graft-versus-host disease with $\hat{I}\pm$ -1-antitrypsin. Blood Advances, 2020, 4, 6098-6105. | 2.5 | 24 |
| 80 | Predictors of Survival and Time to Progression to Myeloid Neoplasm in Patients with Clonal Cytopenias. Blood, 2020, 136, 26-27. | 0.6 | 1 |
| 81 | Hypomagnesemia Is Associated with an Increased Risk of Failure in Patients Diffuse Large B-Cell Lymphoma Undergoing Autologous Stem Cell Transplantation. Blood, 2020, 136, 21-21. | 0.6 | 0 |
| 82 | Autologous Stem Cell Transplantation for Multiple Myeloma Patients Aged $\hat{\%}\%$ 75 Treated with Novel Agents. Blood, 2020, 136, 12-13. | 0.6 | 0 |
| 83 | Spectrum of Hematological Malignancies in 130 Patients with Germline Predisposition Syndromes - Mayo Clinic Germline Predisposition Study. Blood, 2020, 136, 34-35. | 0.6 | 0 |
| 84 | IDH2 Inhibitor Therapy in Relapsed and Refractory Acute Myeloid Leukemia: A Single Institution Experience. Blood, 2020, 136, 43-44. | 0.6 | 0 |
| 85 | Clinical, Molecular, and Prognostic Comparisons between Clonal Cytopenias of Undetermined Significance and Lower-Risk Myelodysplastic Syndromes - a Study of 184 Molecularly Annotated Patients. Blood, 2020, 136, 35-36. | 0.6 | 0 |
| 86 | Decreased Cardiac Ejection Fraction Is Associated with Worse Survival in Patients with Light Chain Amyloidosis Treated with Autologous Stem Cell Transplantation. Blood, 2020, 136, 41-42. | 0.6 | 0 |
| 87 | A Population-Based Study of Chronic Myelomonocytic Leukemia in the United States from 2004-2015. Blood, 2020, 136, 30-31. | 0.6 | 0 |
| 88 | Pre- Transplant Ferritin Predicts Overall Survival and Non-Relapse Mortality in Patients Undergoing Allogeneic Hematopoietic Cell Transplantation for Myelofibrosis. Blood, 2020, 136, 19-20. | 0.6 | 0 |
| 89 | Comparison of reduced intensity conditioning regimens used in patients undergoing hematopoietic stem cell transplantation for myelofibrosis. Bone Marrow Transplantation, 2019, 54, 204-211. | 1.3 | 41 |
| 90 | Comparable outcomes using propylene glycol-free melphalan for autologous stem cell transplantation in multiple myeloma. Bone Marrow Transplantation, 2019, 54, 587-594. | 1.3 | 9 |

| # | ARTICLE | IF | CITATIONS |
|-----|---|-----|-----------|
| 91 | Plasma cell proliferative index post-transplant is a powerful predictor of prognosis in myeloma patients failing to achieve a complete response. <i>Bone Marrow Transplantation</i> , 2019, 54, 442-447. | 1.3 | 7 |
| 92 | Utilization of hematopoietic stem cell transplantation for the treatment of multiple myeloma: a Mayo Stratification of Myeloma and Risk-Adapted Therapy (mSMART) consensus statement. <i>Bone Marrow Transplantation</i> , 2019, 54, 353-367. | 1.3 | 81 |
| 93 | Etiologies of Extreme Thrombocytosis: A Contemporary Series. <i>Mayo Clinic Proceedings</i> , 2019, 94, 1542-1550. | 1.4 | 6 |
| 94 | Prognostic Score and Cytogenetic Risk Classification for Chronic Lymphocytic Leukemia Patients: Center for International Blood and Marrow Transplant Research Report. <i>Clinical Cancer Research</i> , 2019, 25, 5143-5155. | 3.2 | 10 |
| 95 | Fifteen year overall survival rates after autologous stem cell transplantation for AL amyloidosis. <i>American Journal of Hematology</i> , 2019, 94, 1020-1026. | 2.0 | 36 |
| 96 | Impact of consolidation therapy post autologous stem cell transplant in patients with light chain amyloidosis. <i>American Journal of Hematology</i> , 2019, 94, 1066-1071. | 2.0 | 14 |
| 97 | Clinical Applications and Utility of a Precision Medicine Approach for Patients With Unexplained Cytopenias. <i>Mayo Clinic Proceedings</i> , 2019, 94, 1753-1768. | 1.4 | 21 |
| 98 | Outcome of Myelodysplastic Syndromes Over Time in the United States: A National Cancer Data Base Study From 2004-2013. <i>Mayo Clinic Proceedings</i> , 2019, 94, 1467-1474. | 1.4 | 12 |
| 99 | Impact of hospital hospitality house programs on quality of life and mood of patients and caregivers after hematopoietic stem cell transplant. <i>Hematology/ Oncology and Stem Cell Therapy</i> , 2019, 12, 155-160. | 0.6 | 1 |
| 100 | Implementation of a patient blood management program in hematopoietic stem cell transplantation <i>(Editorial, p. 2763)</i>. <i>Transfusion</i> , 2019, 59, 2840-2848. | 0.8 | 11 |
| 101 | Increased fecal primary bile acids in multiple myeloma with engraftment syndrome diarrhea after stem cell transplant. <i>Bone Marrow Transplantation</i> , 2019, 54, 1898-1907. | 1.3 | 1 |
| 102 | The impact of re-induction prior to salvage autologous stem cell transplantation in multiple myeloma. <i>Bone Marrow Transplantation</i> , 2019, 54, 2039-2050. | 1.3 | 9 |
| 103 | Outcomes of Patients with Light Chain Amyloidosis Who Had Autologous Stem Cell Transplantation with 3 or More Organs Involved. <i>Biology of Blood and Marrow Transplantation</i> , 2019, 25, 1520-1525. | 2.0 | 9 |
| 104 | Clinical outcome of patients diagnosed with myelodysplastic syndrome-unclassifiable (MDS-U): single center experience. <i>Leukemia and Lymphoma</i> , 2019, 60, 2483-2487. | 0.6 | 3 |
| 105 | Autologous stem cell transplantation in patients with AL amyloidosis with impaired renal function. <i>Bone Marrow Transplantation</i> , 2019, 54, 1775-1779. | 1.3 | 9 |
| 106 | Utilization and Outcomes of Fertility Preservation Techniques in Women Undergoing Allogeneic Hematopoietic Cell Transplant. <i>Biology of Blood and Marrow Transplantation</i> , 2019, 25, 1232-1239. | 2.0 | 6 |
| 107 | The MAGIC algorithm probability is a validated response biomarker of treatment of acute graft-versus-host disease. <i>Blood Advances</i> , 2019, 3, 4034-4042. | 2.5 | 63 |
| 108 | Autologous Stem Cell Transplant for IgM-Associated Amyloid Light-Chain Amyloidosis. <i>Biology of Blood and Marrow Transplantation</i> , 2019, 25, e108-e111. | 2.0 | 20 |

| # | ARTICLE | IF | CITATIONS |
|-----|---|-----|-----------|
| 109 | Safety and efficacy of propylene glycol-free melphalan as conditioning in patients with AL amyloidosis undergoing stem cell transplantation. <i>Bone Marrow Transplantation</i> , 2019, 54, 1077-1081. | 1.3 | 7 |
| 110 | Frequency of venous thrombotic events in patients with myelodysplastic syndrome and 5q deletion syndrome during lenalidomide therapy. <i>Annals of Hematology</i> , 2019, 98, 331-337. | 0.8 | 5 |
| 111 | Elderly acute lymphoblastic leukemia: a Mayo Clinic study of 124 patients. <i>Leukemia and Lymphoma</i> , 2019, 60, 990-999. | 0.6 | 9 |
| 112 | Differential expression of interferon-induced genes and other tissue-based biomarkers in acute graft-versus-host disease vs. lupus erythematosus in skin. <i>Clinical and Experimental Dermatology</i> , 2019, 44, e81-e88. | 0.6 | 4 |
| 113 | Characteristics and Outcomes of Therapy Related Myeloid Neoplasms in Patients with Multiple Myeloma Following Autologous Stem Cell Transplantation. <i>Blood</i> , 2019, 134, 4560-4560. | 0.6 | 1 |
| 114 | Delayed Neutrophil Engraftment in Patients Receiving Daratumumab As Part of Their First Induction Regimen for Multiple Myeloma. <i>Blood</i> , 2019, 134, 4505-4505. | 0.6 | 0 |
| 115 | Response to Erythropoiesis Stimulating Agents in Patients with WHO-Defined Myelodysplastic Syndrome/Myeloproliferative Neoplasm with Ring Sideroblasts and Thrombocytosis (MDS/MPN-RS-T). <i>Blood</i> , 2019, 134, 4182-4182. | 0.6 | 1 |
| 116 | Phenotypic Correlates and Prognostic Outcomes of TET2 Mutations in Myelodysplastic Syndrome/Myeloproliferative Neoplasm Overlap Syndromes: A Comprehensive Study of 504 Patients. <i>Blood</i> , 2019, 134, 3005-3005. | 0.6 | 0 |
| 117 | The MAGIC Algorithm Probability (MAP): A Novel Laboratory Biomarker for the Response to Treatment of Acute Graft-Versus-Host Disease. <i>Blood</i> , 2019, 134, 367-367. | 0.6 | 0 |
| 118 | Clinical Utility of Telomere Length-Directed Genomic Assessment in Patients with Short Telomere Syndromes. <i>Blood</i> , 2019, 134, 1222-1222. | 0.6 | 0 |
| 119 | Discrepancy of Blast Percentage between the Bone Marrow Aspirate and Flow Cytometry and Its Impact on Survival Outcomes in Patients with Myelodysplastic Syndromes Excess Blast (MDS-EB). <i>Blood</i> , 2019, 134, 5441-5441. | 0.6 | 0 |
| 120 | Risks and Benefits of Bronchoscopy during the First 100 Days Following Allogeneic Hematopoietic Cell Transplantation. <i>Blood</i> , 2019, 134, 4500-4500. | 0.6 | 0 |
| 121 | Correlation of Flow Cytometric Aberrations with Cytogenetic, Molecular Genetic, and Morphology in Patients with Unexplained Cytopenias. <i>Blood</i> , 2019, 134, 5406-5406. | 0.6 | 0 |
| 122 | Acute Myeloid Leukemia with High Risk Features: Routine Central Nervous System Evaluation May be Beneficial. <i>Blood</i> , 2019, 134, 3863-3863. | 0.6 | 1 |
| 123 | Survival Outcomes Following Allogeneic Stem Cell Transplantation for Inherited Bone Marrow Failure and Myeloid Germline Predisposition Syndromes. <i>Blood</i> , 2019, 134, 3300-3300. | 0.6 | 0 |
| 124 | Impact of Targeted Immunotherapies and Novel Cytogenetic and Clinical Risk Groups on Outcome after Allogeneic Hematopoietic Stem Cell Transplant (AlloHCT) for Acute Lymphoblastic Leukemia (ALL): The Mayo Clinic Cohort. <i>Blood</i> , 2019, 134, 2588-2588. | 0.6 | 0 |
| 125 | Use of Maintenance Therapy Post Autologous Stem Cell Transplantation Outside of Clinical Trial Setting for Multiple Myeloma: Single Institution Experience. <i>Blood</i> , 2019, 134, 2013-2013. | 0.6 | 0 |
| 126 | Pre-anthracycline echocardiogram rarely changes treatment strategy in acute myeloid leukemia. <i>American Journal of Hematology</i> , 2018, 93, E144-E146. | 2.0 | 2 |

| # | ARTICLE | IF | CITATIONS |
|-----|---|-----|-----------|
| 127 | Hypomethylating agents (HMAs) effect on myelodysplastic/myeloproliferative neoplasm unclassifiable (MDS/MPN-U): single institution experience. <i>Leukemia and Lymphoma</i> , 2018, 59, 2737-2739. | 0.6 | 9 |
| 128 | Plasma cell proliferative index predicts outcome in immunoglobulin light chain amyloidosis treated with stem cell transplantation. <i>Haematologica</i> , 2018, 103, 1229-1234. | 1.7 | 10 |
| 129 | Analysis of Clinical Factors and Outcomes Associated with Nonuse of Collected Peripheral Blood Stem Cells for Autologous Stem Cell Transplants in Transplant-Eligible Patients with Multiple Myeloma. <i>Biology of Blood and Marrow Transplantation</i> , 2018, 24, 2127-2132. | 2.0 | 21 |
| 130 | Does matching for SNPs in the MHC gamma block in 10/10 HLA-matched unrelated donor-recipient pairs undergoing allogeneic stem cell transplant improve outcomes?. <i>Human Immunology</i> , 2018, 79, 532-536. | 1.2 | 6 |
| 131 | Prognostic interaction between bone marrow morphology and SF3B1 and ASXL1 mutations in myelodysplastic syndromes with ring sideroblasts. <i>Blood Cancer Journal</i> , 2018, 8, 18. | 2.8 | 19 |
| 132 | Allogeneic hematopoietic stem cell transplant overcomes the adverse survival effect of very high risk and unfavorable karyotype in myelofibrosis. <i>American Journal of Hematology</i> , 2018, 93, 649-654. | 2.0 | 40 |
| 133 | Impact of prior melphalan exposure on stem cell collection in light chain amyloidosis. <i>Bone Marrow Transplantation</i> , 2018, 53, 326-333. | 1.3 | 4 |
| 134 | Pretransplant Consolidation Is Not Beneficial for Adults with ALL Undergoing Myeloablative Allogeneic Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2018, 24, 945-955. | 2.0 | 7 |
| 135 | Safety Outcomes for Autologous Stem Cell Transplant in Multiple Myeloma. <i>Mayo Clinic Proceedings</i> , 2018, 93, 56-58. | 1.4 | 16 |
| 136 | Extracorporeal Photopheresis Improves Survival in Hematopoietic Cell Transplant Patients with Bronchiolitis Obliterans Syndrome without Significantly Impacting Measured Pulmonary Functions. <i>Biology of Blood and Marrow Transplantation</i> , 2018, 24, 1906-1913. | 2.0 | 21 |
| 137 | Impact of duration of induction therapy on survival in newly diagnosed multiple myeloma patients undergoing upfront autologous stem cell transplantation. <i>British Journal of Haematology</i> , 2018, 182, 71-77. | 1.2 | 15 |
| 138 | MAGIC biomarkers predict long-term outcomes for steroid-resistant acute GVHD. <i>Blood</i> , 2018, 131, 2846-2855. | 0.6 | 140 |
| 139 | Momelotinib therapy for myelofibrosis: a 7-year follow-up. <i>Blood Cancer Journal</i> , 2018, 8, 29. | 2.8 | 49 |
| 140 | Clinical spectrum and clonal evolution in germline syndromes with predisposition to myeloid neoplasms. <i>British Journal of Haematology</i> , 2018, 182, 141-145. | 1.2 | 4 |
| 141 | Efficacy of biological agents in the treatment of Erdheim-Chester disease. <i>British Journal of Haematology</i> , 2018, 183, 520-524. | 1.2 | 24 |
| 142 | Infusion of autograft natural killer cell/CD14+HLA-DRDIM cell ratio predicts survival in lymphoma post autologous stem cell transplantation. <i>Bone Marrow Transplantation</i> , 2018, 53, 146-154. | 1.3 | 9 |
| 143 | Outcomes of maintenance therapy with lenalidomide or bortezomib in multiple myeloma in the setting of early autologous stem cell transplantation. <i>Leukemia</i> , 2018, 32, 712-718. | 3.3 | 27 |
| 144 | Elevated pre-transplant C-reactive protein identifies a high-risk subgroup in multiple myeloma patients undergoing delayed autologous stem cell transplantation. <i>Bone Marrow Transplantation</i> , 2018, 53, 155-161. | 1.3 | 8 |

| # | ARTICLE | IF | CITATIONS |
|-----|--|-----|-----------|
| 145 | Stem Cell Transplantation for Light Chain Amyloidosis: Decreased Early Mortality Over Time. <i>Journal of Clinical Oncology</i> , 2018, 36, 1323-1329. | 0.8 | 100 |
| 146 | Bortezomib, lenalidomide, and dexamethasone (VRd) followed by autologous stem cell transplant for multiple myeloma. <i>Blood Cancer Journal</i> , 2018, 8, 106. | 2.8 | 16 |
| 147 | Hemolytic Uremic Syndrome Associated With Escherichia coli O157 Infection in an Allogeneic Stem Cell Transplant Recipient. <i>Mayo Clinic Proceedings Innovations, Quality & Outcomes</i> , 2018, 2, 387-391. | 1.2 | 3 |
| 148 | Impact of clone size with a single cytogenetic abnormality on the revised International Prognostic Scoring System in myelodysplastic syndromes. <i>American Journal of Hematology</i> , 2018, 93, E398-E401. | 2.0 | 1 |
| 149 | A novel predictive model of outcome in acute myeloid leukemia without favorable karyotype based on treatment strategy, karyotype and <i>FLT3</i> mutational status. <i>American Journal of Hematology</i> , 2018, 93, E401-E404. | 2.0 | 3 |
| 150 | Amphiregulin modifies the Minnesota Acute Graft-versus-Host Disease Risk Score: results from BMT CTN 0302/0802. <i>Blood Advances</i> , 2018, 2, 1882-1888. | 2.5 | 27 |
| 151 | Light chain type predicts organ involvement and survival in AL amyloidosis patients receiving stem cell transplantation. <i>Blood Advances</i> , 2018, 2, 769-776. | 2.5 | 23 |
| 152 | Prognostic Significance of Stringent Complete Response after Stem Cell Transplantation in Immunoglobulin Light Chain Amyloidosis. <i>Biology of Blood and Marrow Transplantation</i> , 2018, 24, 2360-2364. | 2.0 | 14 |
| 153 | Autologous Stem Cell Transplant for Immunoglobulin Light Chain Amyloidosis Patients Aged 70 to 75. <i>Biology of Blood and Marrow Transplantation</i> , 2018, 24, 2157-2159. | 2.0 | 8 |
| 154 | The clinical outcomes of reclassified erythroleukemia (erythroid/myeloid) as myelodysplastic syndrome (MDS) per 2017 WHO guideline compared to MDS. <i>American Journal of Hematology</i> , 2018, 93, E355-E357. | 2.0 | 2 |
| 155 | Prognostic impact of ASXL1 mutations in patients with myelodysplastic syndromes and multilineage dysplasia with or without ring sideroblasts. <i>Leukemia Research</i> , 2018, 71, 60-62. | 0.4 | 18 |
| 156 | The association of de novo anti-HLA-DPB1 donor-specific antibody formation and primary graft failure after allogeneic hematopoietic cell transplantation. <i>Human Immunology</i> , 2018, 79, 861-864. | 1.2 | 7 |
| 157 | Posttransplant autoimmune encephalitis. <i>Neurology: Neuroimmunology and NeuroInflammation</i> , 2018, 5, e497. | 3.1 | 24 |
| 158 | Mayo Alliance Prognostic Model for Myelodysplastic Syndromes: Integration of Genetic and Clinical Information. <i>Mayo Clinic Proceedings</i> , 2018, 93, 1363-1374. | 1.4 | 20 |
| 159 | Marrow Blast Percentage Impact on High-Grade Myelodysplastic Syndrome By the Revised International Prognostic Scoring System. <i>Blood</i> , 2018, 132, 5510-5510. | 0.6 | 0 |
| 160 | Histopathologic Acute Lung Injury after Allogeneic Hematopoietic Cell Transplantation: Clinical Findings, Radiologic Features, Treatments and Outcomes. <i>Blood</i> , 2018, 132, 2113-2113. | 0.6 | 0 |
| 161 | Bortezomib, Lenalidomide and Dexamethasone (VRD) Followed By Autologous Stem Cell Transplant for Newly Diagnosed Multiple Myeloma; The Mayo Clinic Experience. <i>Blood</i> , 2018, 132, 2147-2147. | 0.6 | 0 |
| 162 | Serial Biomarker Monitoring Early after HCT Identifies Different Risks for Relapse and Graft-Vs-Host Disease. <i>Blood</i> , 2018, 132, 356-356. | 0.6 | 0 |

| # | ARTICLE | IF | CITATIONS |
|-----|---|-----|-----------|
| 163 | Salvage Autologous Stem Cell Transplantation in Multiple Myeloma: Investigating the Impact of Pre-Transplant Therapy. <i>Blood</i> , 2018, 132, 4613-4613. | 0.6 | 0 |
| 164 | Safety and Tolerability of Lurbinectedin (PM01183) in Patients with Acute Myeloid Leukemia and Myelodysplastic Syndrome. <i>Blood</i> , 2018, 132, 2722-2722. | 0.6 | 2 |
| 165 | Efficacy of Mitoxantrone-Based Salvage Therapies in Relapsed or Refractory Acute Myeloid Leukemia in the Mayo Clinic Cancer Center: Analysis of Survival after CLAG-M Vs. MEC. <i>Blood</i> , 2018, 132, 2678-2678. | 0.6 | 0 |
| 166 | Infusion of NKp30/KIR2DL2 Natural Killer Cell Ratio and Survival Post-Autologous Stem Cell Transplantation in Lymphomas. <i>Blood</i> , 2018, 132, 3430-3430. | 0.6 | 0 |
| 167 | 1,123 Consecutive Adults with Non-APL Acute Myeloid Leukemia: The Mayo Clinic Experience. <i>Blood</i> , 2018, 132, 2689-2689. | 0.6 | 0 |
| 168 | Impact of pre-transplant bone marrow plasma cell percentage on post-transplant response and survival in newly diagnosed multiple myeloma. <i>Leukemia and Lymphoma</i> , 2017, 58, 308-315. | 0.6 | 16 |
| 169 | Impact of Post-Transplant Response and Minimal Residual Disease on Survival in Myeloma with High-Risk Cytogenetics. <i>Biology of Blood and Marrow Transplantation</i> , 2017, 23, 598-605. | 2.0 | 47 |
| 170 | The 'HLA conundrum in bone marrow transplantation': correct interpretation of anti-HLA antibodies in haploidentical donor selection. <i>Bone Marrow Transplantation</i> , 2017, 52, 902-904. | 1.3 | 2 |
| 171 | Clinical and Radiologic Responses to Cladribine for the Treatment of Erdheim-Chester Disease. <i>JAMA Oncology</i> , 2017, 3, 1253. | 3.4 | 47 |
| 172 | High prevalence of monoclonal gammopathy among patients with warm autoimmune hemolytic anemia. <i>American Journal of Hematology</i> , 2017, 92, E164-E166. | 2.0 | 5 |
| 173 | Revisiting conditioning dose in newly diagnosed light chain amyloidosis undergoing frontline autologous stem cell transplant: impact on response and survival. <i>Bone Marrow Transplantation</i> , 2017, 52, 1126-1132. | 1.3 | 30 |
| 174 | Safety and Efficacy of Infliximab Therapy in the Setting of Steroid-Refractory Acute Graft-versus-Host Disease. <i>Biology of Blood and Marrow Transplantation</i> , 2017, 23, 1478-1484. | 2.0 | 31 |
| 175 | Outcome of elderly patients after failure to hypomethylating agents given as frontline therapy for acute myeloid leukemia: Single institution experience*. <i>American Journal of Hematology</i> , 2017, 92, 866-871. | 2.0 | 17 |
| 176 | Safety and feasibility of lower antithrombin replacement targets in adult patients with hematological malignancies receiving asparaginase therapy. <i>Leukemia and Lymphoma</i> , 2017, 58, 2588-2597. | 0.6 | 12 |
| 177 | Emergencies in Hematology and Oncology. <i>Mayo Clinic Proceedings</i> , 2017, 92, 609-641. | 1.4 | 27 |
| 178 | Immunophenotypic and molecular comparison between allogeneic and autologous graft-versus-host disease of the skin: A retrospective study using immunohistochemical and proteomics methods. <i>Journal of Cutaneous Pathology</i> , 2017, 44, 1087-1091. | 0.7 | 2 |
| 179 | A phase 1 trial of 90Y-Zevalin radioimmunotherapy with autologous stem cell transplant for multiple myeloma. <i>Bone Marrow Transplantation</i> , 2017, 52, 1372-1377. | 1.3 | 13 |
| 180 | Serial measurements of circulating plasma cells before and after induction therapy have an independent prognostic impact in patients with multiple myeloma undergoing upfront autologous transplantation. <i>Haematologica</i> , 2017, 102, 1439-1445. | 1.7 | 29 |

| # | ARTICLE | IF | CITATIONS |
|-----|--|-----|-----------|
| 181 | Current treatment preferences in chronic myeloid leukemia: The Mayo Clinic Physicians' survey. <i>American Journal of Hematology</i> , 2017, 92, E626-E627. | 2.0 | 3 |
| 182 | Clinical and radiological responses to oral methotrexate alone or in combination with other agents in Erdheim-Chester disease. <i>Blood Cancer Journal</i> , 2017, 7, 647. | 2.8 | 8 |
| 183 | Safety and Efficacy of Fecal Microbiota Transplant for Recurrent <i>Clostridium difficile</i> Infection in Patients With Cancer Treated With Cytotoxic Chemotherapy: A Single-Institution Retrospective Case Series. <i>Mayo Clinic Proceedings</i> , 2017, 92, 1617-1624. | 1.4 | 53 |
| 184 | Clinical outcomes of <sc>HLA</sc>â€<sc>DPB</sc>1 mismatches in 10/10 <sc>HLA</sc>â€matched unrelated donorâ€recipient pairs undergoing allogeneic stem cell transplant. <i>European Journal of Haematology</i> , 2017, 99, 275-282. | 1.1 | 11 |
| 185 | The impact of induction regimen on transplant outcome in newly diagnosed multiple myeloma in the era of novel agents. <i>Bone Marrow Transplantation</i> , 2017, 52, 34-40. | 1.3 | 30 |
| 186 | Metabolic syndrome and cardiovascular disease following hematopoietic cell transplantation: screening and preventive practice recommendations from CIBMTR and EBMT. <i>Bone Marrow Transplantation</i> , 2017, 52, 173-182. | 1.3 | 61 |
| 187 | Blinatumomab-induced lineage switch of B-ALL with t(4:11)(q21;q23) KMT2A/AFF1 into an aggressive AML: pre- and post-switch phenotypic, cytogenetic and molecular analysis. <i>Blood Cancer Journal</i> , 2017, 7, e607-e607. | 2.8 | 52 |
| 188 | An early-biomarker algorithm predicts lethal graft-versus-host disease and survival. <i>JCI Insight</i> , 2017, 2, e89798. | 2.3 | 166 |
| 189 | Immune-Mediated Autonomic Neuropathies following Allogeneic Stem Cell Transplantation in Acute Myeloid Leukemia. <i>Case Reports in Hematology</i> , 2017, 2017, 1-4. | 0.3 | 0 |
| 190 | The D-Index Does Not Predict Invasive Fungal Infection (IFI) Among Allogeneic Hematopoietic Stem Cell Transplant (HSCT) Recipients.. <i>Open Forum Infectious Diseases</i> , 2016, 3, . | 0.4 | 0 |
| 191 | Stem cell transplantation compared with melphalan plus dexamethasone in the treatment of immunoglobulin lightâ€chain amyloidosis. <i>Cancer</i> , 2016, 122, 2197-2205. | 2.0 | 37 |
| 192 | Autologous stem cell transplant for multiple myeloma patients 70 years or older. <i>Bone Marrow Transplantation</i> , 2016, 51, 1449-1455. | 1.3 | 51 |
| 193 | Medical Students' Knowledge, Familiarity, and Attitudes towards Hematopoietic Stem Cell Donation. <i>Biology of Blood and Marrow Transplantation</i> , 2016, 22, 1710-1716. | 2.0 | 24 |
| 194 | Risk stratification in myeloma by detection of circulating plasma cells prior to autologous stem cell transplantation in the novel agent era. <i>Blood Cancer Journal</i> , 2016, 6, e512-e512. | 2.8 | 38 |
| 195 | Late acute graft-versus-host disease: a prospective analysis of clinical outcomes and circulating angiogenic factors. <i>Blood</i> , 2016, 128, 2350-2358. | 0.6 | 43 |
| 196 | Metabolic Syndrome and Cardiovascular Disease after Hematopoietic Cell Transplantation: Screening and Preventive Practice Recommendations from the CIBMTR and EBMT. <i>Biology of Blood and Marrow Transplantation</i> , 2016, 22, 1493-1503. | 2.0 | 55 |
| 197 | Consensus Opinion on Allogeneic Hematopoietic Cell Transplantation in Advanced Systemic Mastocytosis. <i>Biology of Blood and Marrow Transplantation</i> , 2016, 22, 1348-1356. | 2.0 | 76 |
| 198 | Azithromycin for the Treatment of Obliterative Bronchiolitis after Hematopoietic Stem Cell Transplantation: A Systematic Review and Meta-Analysis. <i>Biology of Blood and Marrow Transplantation</i> , 2016, 22, 2264-2269. | 2.0 | 29 |

| # | ARTICLE | IF | CITATIONS |
|-----|---|-----|-----------|
| 199 | Employment Status as an Indicator of Recovery and Function One Year after Hematopoietic Stem Cell Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2016, 22, 1690-1695. | 2.0 | 51 |
| 200 | Vancomycin-resistant <i>Enterococcus</i> colonization and bloodstream infection: prevalence, risk factors, and the impact on early outcomes after allogeneic hematopoietic cell transplantation in patients with acute myeloid leukemia. <i>Transplant Infectious Disease</i> , 2016, 18, 913-920. | 0.7 | 40 |
| 201 | Deletion 5q is frequent in myelodysplastic syndrome (MDS) patients diagnosed with interstitial lung diseases (ILD): Mayo Clinic experience. <i>Leukemia Research</i> , 2016, 50, 112-115. | 0.4 | 8 |
| 202 | Thrombotic Microangiopathy Care Pathway: A Consensus Statement for the Mayo Clinic Complement Alternative Pathway-Thrombotic Microangiopathy (CAP-TMA) Disease-Oriented Group. <i>Mayo Clinic Proceedings</i> , 2016, 91, 1189-1211. | 1.4 | 55 |
| 203 | Fludarabine-Busulfan Reduced-Intensity Conditioning in Comparison with Fludarabine-Melphalan Is Associated with Increased Relapse Risk In Spite of Pharmacokinetic Dosing. <i>Biology of Blood and Marrow Transplantation</i> , 2016, 22, 1431-1439. | 2.0 | 26 |
| 204 | Prior hypomethylating agent use lacks impact on clinical outcome in patients with secondary acute myeloid leukemia arising from myelodysplastic syndromes treated with standard induction chemotherapy. <i>International Journal of Hematology</i> , 2016, 103, 409-415. | 0.7 | 0 |
| 205 | Corticosteroid use as adjunct therapy for respiratory syncytial virus infection in adult allogeneic stem cell transplant recipients. <i>Transplant Infectious Disease</i> , 2016, 18, 216-226. | 0.7 | 14 |
| 206 | ABO blood group incompatibility as an adverse risk factor for outcomes in patients with myelodysplastic syndromes and acute myeloid leukemia undergoing HLA-matched peripheral blood hematopoietic cell transplantation after reduced-intensity conditioning. <i>Transfusion</i> , 2016, 56, 518-527. | 0.8 | 14 |
| 207 | Hypomethylating agents are effective in shrinking splenomegaly in patients with chronic myelomonocytic leukemia. <i>Leukemia and Lymphoma</i> , 2016, 57, 1714-1715. | 0.6 | 7 |
| 208 | The impact of dialysis on the survival of patients with immunoglobulin light chain (AL) amyloidosis undergoing autologous stem cell transplantation. <i>Nephrology Dialysis Transplantation</i> , 2016, 31, 1284-1289. | 0.4 | 25 |
| 209 | International, Multicenter Standardization of Acute Graft-versus-Host Disease Clinical Data Collection: A Report from the Mount Sinai Acute GVHD International Consortium. <i>Biology of Blood and Marrow Transplantation</i> , 2016, 22, 4-10. | 2.0 | 487 |
| 210 | The Incidence and Severity of Oral Mucositis among Allogeneic Hematopoietic Stem Cell Transplantation Patients: A Systematic Review. <i>Biology of Blood and Marrow Transplantation</i> , 2016, 22, 605-616. | 2.0 | 103 |
| 211 | Correlation of Pain and Fluoride Concentration in Allogeneic Hematopoietic Stem Cell Transplant Recipients on Voriconazole. <i>Biology of Blood and Marrow Transplantation</i> , 2016, 22, 579-583. | 2.0 | 19 |
| 212 | Momelotinib Therapy in Myelofibrosis: 6-Years Follow-up Data on Safety, Efficacy and the Impact of Mutations on Overall and Relapse-Free Survival. <i>Blood</i> , 2016, 128, 1123-1123. | 0.6 | 4 |
| 213 | Myeloid Sarcoma: The Mayo Clinic Experience of Ninety Six Case Series. <i>Blood</i> , 2016, 128, 2798-2798. | 0.6 | 3 |
| 214 | Deficiency of Current Acute Myeloid Leukemia (AML) Response Criteria to Predict Response to Hypomethylating Agent Therapy: The Value of Long-Lasting Stable Disease. <i>Blood</i> , 2016, 128, 2799-2799. | 0.6 | 5 |
| 215 | Outcome of Myelodysplastic Syndromes over Time in the US: A National Cancer Data Base Study from 2004-2013. <i>Blood</i> , 2016, 128, 3604-3604. | 0.6 | 3 |
| 216 | Feasibility of Allogeneic Hematopoietic Stem Cell Transplant for High Risk FLT3-ITD Mutant Patients with Acute Myeloid Leukemia in CR1- a Real Word Analysis. <i>Blood</i> , 2016, 128, 4694-4694. | 0.6 | 1 |

| # | ARTICLE | IF | CITATIONS |
|-----|--|-----|-----------|
| 217 | An Early Biomarker Algorithm Predicts Lethal Graft-Versus-Host Disease and Survival after Allogeneic Hematopoietic Cell Transplantation. <i>Blood</i> , 2016, 128, 509-509. | 0.6 | 1 |
| 218 | Overview of the progress on haploidentical hematopoietic transplantation. <i>World Journal of Transplantation</i> , 2016, 6, 665. | 0.6 | 14 |
| 219 | Outcome of Elderly Patients after Failure to Hypomethylating Agents Given As Frontline Therapy for Acute Myeloid Leukemia (AML): Single Institution Experience. <i>Blood</i> , 2016, 128, 1617-1617. | 0.6 | 0 |
| 220 | Clinical Spectrum of Germline Mutations with Predisposition to Myeloid Neoplasms- 2016 World Health Organization Classification Update. <i>Blood</i> , 2016, 128, 300-300. | 0.6 | 0 |
| 221 | A Risk Stratification Model Using Quantification of Circulating Plasma Cells in Multiple Myeloma Prior to Autologous Stem Cell Transplantation in the Era of Novel Agents. <i>Blood</i> , 2016, 128, 996-996. | 0.6 | 0 |
| 222 | Day +30 and Day +100 CD33 Chimerisms Predict Survival after Allogeneic Hematopoietic Stem Cell Transplantation in Patients with Myelofibrosis. <i>Blood</i> , 2016, 128, 4653-4653. | 0.6 | 0 |
| 223 | Clinical Features and Outcomes of Isolated Myeloid Sarcoma in the United States: Analysis Using a National Dataset. <i>Blood</i> , 2016, 128, 1618-1618. | 0.6 | 2 |
| 224 | Clinical Outcomes Related to the Use of Monoclonal Antibody Therapy for Steroid Refractory Acute Graft-Versus Host Disease after Allogeneic Hematopoietic Cell Transplantation. <i>Blood</i> , 2016, 128, 4593-4593. | 0.6 | 0 |
| 225 | Biomarkers Predict Graft-Vs-Host Disease Outcomes Better Than Clinical Response after One Week of Treatment. <i>Blood</i> , 2016, 128, 510-510. | 0.6 | 0 |
| 226 | Bortezomib, Melphalan and Low Dose TBI Conditioning for Patients Undergoing Autologous Stem Cell Transplantation for Multiple Myeloma. <i>Blood</i> , 2016, 128, 2267-2267. | 0.6 | 0 |
| 227 | Safety and Efficacy of Fecal Microbiota Transplantation for Recurrent Clostridium Infection in Patients with Hematologic Malignancies. <i>Blood</i> , 2016, 128, 3599-3599. | 0.6 | 0 |
| 228 | Infused autograft lymphocyte-to-monocyte ratio and survival in T-cell lymphoma post-autologous peripheral blood hematopoietic stem cell transplantation. <i>Journal of Hematology and Oncology</i> , 2015, 8, 80. | 6.9 | 7 |
| 229 | Infused autograft lymphocyte to monocyte ratio predicts survival in classical Hodgkin lymphoma. <i>Journal of Blood Medicine</i> , 2015, 6, 45. | 0.7 | 8 |
| 230 | Impact of Alemtuzumab Therapy and Route of Administration in T-Prolymphocytic Leukemia: AASingle-Center Experience. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2015, 15, 699-704. | 0.2 | 11 |
| 231 | Monosomal Karyotype Predicts Adverse Prognosis in Patients Diagnosed With Chronic Myelomonocytic Leukemia: A Single-Institution Experience. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2015, 15, e39-e41. | 0.2 | 6 |
| 232 | Genetic determinants of response and survival in momelotinib-treated patients with myelofibrosis. <i>Leukemia</i> , 2015, 29, 741-744. | 3.3 | 38 |
| 233 | Trends and Outcomes in Allogeneic Hematopoietic Stem Cell Transplant for Multiple Myeloma at Mayo Clinic. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2015, 15, 349-357.e2. | 0.2 | 10 |
| 234 | Primary Myelodysplastic Syndromes. <i>Mayo Clinic Proceedings</i> , 2015, 90, 1623-1638. | 1.4 | 16 |

| # | ARTICLE | IF | CITATIONS |
|-----|--|-----|-----------|
| 235 | Momelotinib treatmentâ€emergent neuropathy: prevalence, risk factors and outcome in 100 patients with myelofibrosis. <i>British Journal of Haematology</i> , 2015, 169, 77-80. | 1.2 | 56 |
| 236 | Patients With Therapy-Related CMML Have Shorter Median Overall Survival Than Those With De Novo CMML: Mayo Clinic Long-Term Follow-Up Experience. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2015, 15, 546-549. | 0.2 | 20 |
| 237 | Prognostic impact of combined NPM1+/FLT3âˆ™ genotype in patients with acute myeloid leukemia with intermediate risk cytogenetics stratified by age and treatment modalities. <i>Leukemia Research</i> , 2015, 39, 1207-1213. | 0.4 | 7 |
| 238 | Outcomes of plasma exchange in patients with transplantâ€associated thrombotic microangiopathy based on time of presentation since transplant. <i>Journal of Clinical Apheresis</i> , 2015, 30, 147-153. | 0.7 | 22 |
| 239 | Revised assessment of response and long-term discontinuation rates among 111 patients with myelofibrosis treated with momelotinib or ruxolitinib. <i>Leukemia</i> , 2015, 29, 498-500. | 3.3 | 20 |
| 240 | Novel Genetic Variants in Complement-Mediated Thrombotic Microangiopath. <i>Blood</i> , 2015, 126, 1050-1050. | 0.6 | 3 |
| 241 | Early T-Lymphocyte Chimerism Kinetics Is Influenced By Conditioning Regimen in Reduced Intensity Allogeneic Stem Cell Transplantation. <i>Blood</i> , 2015, 126, 1923-1923. | 0.6 | 1 |
| 242 | Prognostic Impact of Peripheral Blood Count Recovery and Cytogenetic Remission Prior to Reduced Intensity Allogeneic Transplantation in Patients with Acute Myelogenous Leukemia and Myelodysplastic Syndromes. <i>Blood</i> , 2015, 126, 3210-3210. | 0.6 | 1 |
| 243 | Patients with Therapy-Related Myelodysplastic Syndromes (t-MDS) Have Shorter Median Overall Survival Than De Novo MDS: Mayo Clinic Experience. <i>Blood</i> , 2015, 126, 5234-5234. | 0.6 | 3 |
| 244 | Fludarabine Busulfan Compared to Fludarabine Melphalan Is Associated with Increased Relapse Risk in Reduced Intensity Conditioning Transplant Despite Pharmacokinetic Dosing. <i>Blood</i> , 2015, 126, 736-736. | 0.6 | 2 |
| 245 | Prognostic Correlates and Outcomes of Relapsed T-Cell Acute Lymphoblastic Leukemia/Lymphoma: An Analysis of 41 Consecutive Patients. <i>Blood</i> , 2015, 126, 3730-3730. | 0.6 | 0 |
| 246 | Response to Hypomethylating Agents in Myelodysplastic Syndromes Based on WHO 2008 Subtypes and IPSS-R Stratification and Impact on Survival. <i>Blood</i> , 2015, 126, 5260-5260. | 0.6 | 0 |
| 247 | Momelotinib Therapy for Myelofibrosis: Impact on Long-Term Survival and Genotype Correlations. <i>Blood</i> , 2015, 126, 4062-4062. | 0.6 | 0 |
| 248 | Clinical Characteristics and Outcome of Adult Acute Erythroleukemia; Mayo Clinic Experience. <i>Blood</i> , 2015, 126, 4980-4980. | 0.6 | 0 |
| 249 | Guidelines for the Standardization of Acute Graft-Versus-Host Disease Clinical Data Collection: An International Consensus Report. <i>Blood</i> , 2015, 126, 3154-3154. | 0.6 | 0 |
| 250 | Survival Trends in Adult T-Acute Lymphoblastic Leukemia / Lymphoma (ALL), a Comparative Analysis of 92 Patients By Year of Diagnosis. <i>Blood</i> , 2015, 126, 2490-2490. | 0.6 | 0 |
| 251 | Clofarabine Based Chemotherapy in Adult Relapsed/Refractory Acute Lymphoblastic Leukemia/Lymphoma-a Single Institution Experience. <i>Blood</i> , 2015, 126, 4910-4910. | 0.6 | 0 |
| 252 | Clinical Outcome of Therapy-Related Acute Myeloid Leukemia Is Strongly Related to Cytogenetic Analysis. <i>Blood</i> , 2015, 126, 1401-1401. | 0.6 | 0 |

| # | ARTICLE | IF | CITATIONS |
|-----|--|-----|-----------|
| 253 | Early CMV Infection Detected By Quantitative Nucleic Acid Testing (QNAT) Is Associated with Lower Risk of Relapse after Reduced Intensity, but Not Myeloablative, Hematopoietic Cell Transplantation in Acute Myeloid Leukemia. <i>Blood</i> , 2015, 126, 1913-1913. | 0.6 | 0 |
| 254 | The Adverse Impact of Age and Central Nervous System Involvement on Survival in Adult T-ALL, an Analysis of 92 Consecutive Patients. <i>Blood</i> , 2015, 126, 4993-4993. | 0.6 | 0 |
| 255 | Clinical Outcome of Hypomethylating Agents in Hypocellular MDS: Mayo Clinic Experience. <i>Blood</i> , 2015, 126, 5254-5254. | 0.6 | 0 |
| 256 | A Single Institution Study of Allogeneic Hematopoietic Stem Cell Transplant for MDS and AML in Patients 60 Years of Age and Older: Impact of Disease Risk Index and Secondary Disease. <i>Blood</i> , 2015, 126, 5532-5532. | 0.6 | 0 |
| 257 | The Role of Spleen Directed Therapy and Predictors of Outcomes with Reduced Intensity Conditioning Allogeneic Hematopoietic Stem Cell Transplantation for Patients with Primary Myelofibrosis and Splenomegaly. <i>Blood</i> , 2015, 126, 4370-4370. | 0.6 | 0 |
| 258 | The Impact of Induction Regimen Choice on Transplant Outcome and Survival in Newly Diagnosed Multiple Myeloma in the Era of Novel Agents. <i>Blood</i> , 2015, 126, 3044-3044. | 0.6 | 0 |
| 259 | Extracorporeal photopheresis for chronic graft-versus-host disease: a systematic review and meta-analysis. <i>Blood Research</i> , 2014, 49, 100. | 0.5 | 56 |
| 260 | Cost-Effectiveness analysis of early vs. late autologous stem cell transplantation in multiple myeloma. <i>Clinical Transplantation</i> , 2014, 28, 1084-1091. | 0.8 | 21 |
| 261 | Infused Autograft Lymphocyte to Monocyte Ratio and Survival in Diffuse Large B Cell Lymphoma. <i>Biology of Blood and Marrow Transplantation</i> , 2014, 20, 1804-1812. | 2.0 | 22 |
| 262 | Hematopoietic Stem-Cell Transplantation for Advanced Systemic Mastocytosis. <i>Journal of Clinical Oncology</i> , 2014, 32, 3264-3274. | 0.8 | 146 |
| 263 | Monosomal karyotype in Philadelphia chromosome-negative acute lymphoblastic leukemia. <i>Blood Cancer Journal</i> , 2013, 3, e122-e122. | 2.8 | 14 |
| 264 | Cost-Effectiveness Analysis of a Risk-Adapted Algorithm of Plerixafor Use for Autologous Peripheral Blood Stem Cell Mobilization. <i>Biology of Blood and Marrow Transplantation</i> , 2013, 19, 87-93. | 2.0 | 76 |
| 265 | Second auto-SCT for treatment of relapsed multiple myeloma. <i>Bone Marrow Transplantation</i> , 2013, 48, 568-573. | 1.3 | 59 |
| 266 | Safety and efficacy of CYT387, a JAK1 and JAK2 inhibitor, in myelofibrosis. <i>Leukemia</i> , 2013, 27, 1322-1327. | 3.3 | 212 |
| 267 | Refinement in patient selection to reduce treatment-related mortality from autologous stem cell transplantation in amyloidosis. <i>Bone Marrow Transplantation</i> , 2013, 48, 557-561. | 1.3 | 158 |
| 268 | Cost-Effectiveness Of Antithrombin Repletion In Adult Patients With Acute Lymphoblastic Leukemia (ALL) Treated With Asparaginase-Containing Combination Chemotherapy; A Single Center Experience. <i>Blood</i> , 2013, 122, 1732-1732. | 0.6 | 1 |
| 269 | Clonal Evolution As Determined By Sequential Bone Marrow Karyotype Analysis During JAK Inhibitor Therapy For Myelofibrosis: Impact On Treatment Response and Overall and Leukemia-Free Survival. <i>Blood</i> , 2013, 122, 2821-2821. | 0.6 | 1 |
| 270 | Retrospective Comparison Of Survival and Leukemic Transformation In Myelofibrosis Patients Treated With Ruxolitinib Versus Momelotinib Versus Fedratinib Versus Pomalidomide. <i>Blood</i> , 2013, 122, 4049-4049. | 0.6 | 1 |

| # | ARTICLE | IF | CITATIONS |
|-----|--|-----|-----------|
| 271 | Hepatic and Metabolic Complications In Adult Patients With Acute Lymphoblastic Leukemia (ALL) Treated With Asparaginase-Containing Combination Chemotherapy: A Single Center Experience. Blood, 2013, 122, 1405-1405. | 0.6 | 0 |
| 272 | Autologous Stem Cell Transplantation In Immunoglobulin Light Chain Amyloidosis With Factor X Deficien. Blood, 2013, 122, 2151-2151. | 0.6 | 9 |
| 273 | Allogeneic Hematopoietic Cell Transplantation Is Effective In Patients With Advanced Systemic Mastocytosis: A Multicenter Retrospective Analysis. Blood, 2013, 122, 2145-2145. | 0.6 | 0 |
| 274 | Familial Myeloid Neoplasms: Clinical Spectrum and Associated Abnormalities. Blood, 2013, 122, 2794-2794. | 0.6 | 0 |
| 275 | Extracorporeal Photophoresis (ECP) For Chronic Graft Versus Host Disease (cGVHD): A Systemic Review and Meta-Analysis. Blood, 2013, 122, 5472-5472. | 0.6 | 0 |
| 276 | Baseline Spleen Size and Mutations Involving ASXL1 and SRSF2 Predict Survival and Treatment Response In JAK Inhibitor Treated Myelofibrosis Patients. Blood, 2013, 122, 4048-4048. | 0.6 | 0 |
| 277 | Cytogenetic Abnormalities Predict Clinical Outcome In Patients Diagnosed With Relapsed Acute Myeloid Leukemia (rAML): Single Center Experience. Blood, 2013, 122, 4955-4955. | 0.6 | 0 |
| 278 | A Novel Prognostic Model To Predict Relapse After Allogeneic Stem Cell Transplantation For Myelodysplastic Syndromes. Blood, 2013, 122, 2098-2098. | 0.6 | 0 |
| 279 | Correlation Of Outcomes Of Allogeneic Stem Cell Transplants For Chronic Myelomonocytic Leukemia With The Mayo Prognostic Model. Blood, 2013, 122, 5226-5226. | 0.6 | 0 |
| 280 | Thromboembolic and Hemorrhagic Complications In Adult Patients With Acute Lymphoblastic Leukemia (ALL) Treated With Asparaginase-Containing Combination Chemotherapy: A Single Center Experience. Blood, 2013, 122, 3873-3873. | 0.6 | 1 |
| 281 | Monosomal Karyotype Predicts Adverse Prognosis In Patients With Chronic Myelomonocytic Leukemia. Blood, 2013, 122, 1334-1334. | 0.6 | 1 |
| 282 | Voriconazole Exposure and The Risk Of Cutaneous Squamous Cell Carcinoma In Allogeneic Hematopoietic Stem Cell Transplant Patients. Blood, 2013, 122, 916-916. | 0.6 | 0 |
| 283 | Chronic Graft Vs Host Disease Is The Strongest Predictor Of Outcome After Reduced Intensity Conditioning Stem Cell Transplantation In Chronic Lymphocytic Leukemia and Is Associated With Pretransplant B Cell Characteristics. Blood, 2013, 122, 3375-3375. | 0.6 | 0 |
| 284 | Extramedullary Leukemia Relapse In Patients With Acute Myeloid Leukemia Allogeneic Stem Cell Transplantation: Risk Factors and Prognosis. Blood, 2013, 122, 2081-2081. | 0.6 | 0 |
| 285 | Management Of PICC-Associated Thrombosis In Patients Receiving Chemotherapy For Hematologic Malignancies. Blood, 2013, 122, 5000-5000. | 0.6 | 0 |
| 286 | Risk Factors and Outcome of Pulmonary Complications After Autologous Hematopoietic Stem Cell Transplant. Chest, 2012, 141, 442-450. | 0.4 | 87 |
| 287 | Early versus delayed autologous transplantation after immunomodulatory agents-based induction therapy in patients with newly diagnosed multiple myeloma. Cancer, 2012, 118, 1585-1592. | 2.0 | 106 |
| 288 | Doxycycline Used As Post Transplant Antibacterial Prophylaxis Improves Survival in Patients with Light Chain Amyloidosis Undergoing Autologous Stem Cell Transplantation.. Blood, 2012, 120, 3138-3138. | 0.6 | 26 |

| # | ARTICLE | IF | CITATIONS |
|-----|---|-----|-----------|
| 289 | Cost Effectiveness Decision Tree Analysis of Early Versus Late Autologous Stem Cell Transplantation (ASCT) in Multiple Myeloma (MM) in the United States (US). <i>Blood</i> , 2012, 120, 602-602. | 0.6 | 1 |
| 290 | Tacrolimus/Sirolimus Vs. Tacrolimus/Methotrexate for Graft-Vs.-Host Disease Prophylaxis After HLA-Matched, Related Donor Hematopoietic Stem Cell Transplantation: Results of Blood and Marrow Transplant Clinical Trials Network Trial 0402. <i>Blood</i> , 2012, 120, 739-739. | 0.6 | 19 |
| 291 | Treatment-Related AML Patients Previously Treated with Taxanes for Breast Cancer Have Similar Outcomes As De Novo AML. <i>Blood</i> , 2012, 120, 3555-3555. | 0.6 | 6 |
| 292 | Patients with Immunoglobulin Light Chain Amyloidosis (AL) Undergoing High Dose Chemotherapy with Autologous Stem Cell Transplantation (ASCT) have Superior Outcomes As Compared to Patients with Multiple Myeloma (MM). <i>Blood</i> , 2012, 120, 600-600. | 0.6 | 0 |
| 293 | Loss of the Y Chromosome Predicts Lower Complete Cytogenetic Remission Rate in Patients (pts) with Chronic Myeloid Leukemia (CML). <i>Blood</i> , 2012, 120, 4804-4804. | 0.6 | 0 |
| 294 | Allogeneic Stem Cell Transplantation for Primary and Post ET/PV Myelofibrosis At Mayo Clinic: A Retrospective Review Across a Geographically Diverse 3 Site Cancer Center.. <i>Blood</i> , 2012, 120, 2850-2850. | 0.6 | 0 |
| 295 | Lack of Prognostic Significance of Monosomal Karyotype and Absolute Lymphocyte Count At Diagnosis in Philadelphia Chromosome Negative Acute Lymphoblastic Leukemia. <i>Blood</i> , 2012, 120, 1476-1476. | 0.6 | 1 |
| 296 | Analysis of Stem Cell Transplant Referral in a Cohort of Newly Diagnosed Chronic Lymphocytic Leukemia Patients. <i>Blood</i> , 2012, 120, 4252-4252. | 0.6 | 0 |
| 297 | Refinement in Patient Selection to Reduce Treatment-Related Mortality From Stem Cell Transplantation in Amyloidosis. <i>Blood</i> , 2012, 120, 599-599. | 0.6 | 0 |
| 298 | Pomalidomide Therapy for Myelofibrosis: Analysis of Results From Three Consecutive Clinical Trials. <i>Blood</i> , 2011, 118, 1759-1759. | 0.6 | 1 |
| 299 | A Phase I Trial of Zevalin Radioimmunotherapy with High-Dose Melphalan (HDM) and Autologous Stem Cell Transplant (ASCT) for Multiple Myeloma (MM). <i>Blood</i> , 2011, 118, 3095-3095. | 0.6 | 1 |
| 300 | An Expanded Multicenter Phase I/II Study of CYT387, a JAK- 1/2 Inhibitor for the Treatment of Myelofibrosis,. <i>Blood</i> , 2011, 118, 3849-3849. | 0.6 | 16 |
| 301 | The Timing of Acute Renal Failure Strongly Affects Survival of Immunoglobulin Light Chain (AL) Amyloidosis Patients Undergoing Autologous Stem Cell Transplantation,. <i>Blood</i> , 2011, 118, 4120-4120. | 0.6 | 5 |
| 302 | Alemtuzumab Use and Survival After Reduced Intensity Allogeneic Stem Cell Transplantation in High-Risk Chronic Lymphocytic Leukemia (CLL),. <i>Blood</i> , 2011, 118, 4152-4152. | 0.6 | 1 |
| 303 | Long-Term Outcome of Treatment with Ruxolitinib in Myelofibrosis. <i>Blood</i> , 2011, 118, 1752-1752. | 0.6 | 2 |
| 304 | Impact of Rapid Lymphocyte and Monocyte Recovery on Overall Survival Post-Allogeneic Hematopoietic Stem Cell Transplantation (HSCT) with Fludarabine/Melphalan Conditioning. <i>Blood</i> , 2011, 118, 3040-3040. | 0.6 | 0 |
| 305 | Autologous stem cell transplant for immunoglobulin light chain amyloidosis: a status report. <i>Leukemia and Lymphoma</i> , 2010, 51, 2181-2187. | 0.6 | 102 |
| 306 | Outcome of Transplantation for Myelofibrosis. <i>Biology of Blood and Marrow Transplantation</i> , 2010, 16, 358-367. | 2.0 | 245 |

| # | ARTICLE | IF | CITATIONS |
|-----|---|-----|-----------|
| 307 | Transplantation for Immunoglobulin Light Chain Amyloidosis. A Statistical Analysis of Factors Predicting Outcome In Over 400 Patients. <i>Blood</i> , 2010, 116, 3557-3557. | 0.6 | 1 |
| 308 | Collection of Stem Cell Early In the Disease Course of Multiple Myeloma Is Associated with Early Engraftment.. <i>Blood</i> , 2010, 116, 4518-4518. | 0.6 | 0 |
| 309 | A Phase-2 Trial of Low-Dose Pomalidomide In Myelofibrosis with Anemia. <i>Blood</i> , 2010, 116, 4109-4109. | 0.6 | 1 |
| 310 | Peripheral Blood Stem Cell Collection In Patients Undergoing Induction Therapy with Lenalidomide Based Regimens: Failure Rates and Salvage Approaches. <i>Blood</i> , 2010, 116, 2253-2253. | 0.6 | 5 |
| 311 | Acute Renal Failure Is a Common Presentation of Engraftment Syndrome In Light Chain Amyloidosis (AL) Patients After Autologous Stem Cell transplantation.. <i>Blood</i> , 2010, 116, 3468-3468. | 0.6 | 0 |
| 312 | Trend towards Improved Day 100 and 2-Year Survival After SCT for AL Amyloidosis: Outcomes Before and After 2006. <i>Blood</i> , 2010, 116, 3554-3554. | 0.6 | 13 |
| 313 | Stem Cell Transplant without Growth Factor In Multiple Myeloma: Engraftment Kinetics, Bacteremia, and Hospitalization.. <i>Blood</i> , 2010, 116, 3469-3469. | 0.6 | 0 |
| 314 | Comparison of Troponin T and N-Terminal-Pro-Brain Natriuretic Peptides In Two Models of Treatment Related Mortality In AL Amyloidosis Patients Following Autologous Stem Cell Transplantation. <i>Blood</i> , 2010, 116, 3572-3572. | 0.6 | 6 |
| 315 | Novel Agents for Initial Therapy of Multiple Myeloma: Comparable Results with Continued Initial Therapy and Delayed Transplantation at Relapse Versus Early Transplantation.. <i>Blood</i> , 2009, 114, 956-956. | 0.6 | 1 |
| 316 | Low risk for symptomatic venous thromboembolic events (vte) during cytokine administration for peripheral blood stem cell mobilization. <i>Journal of Clinical Oncology</i> , 2009, 27, 7039-7039. | 0.8 | 0 |
| 317 | Autologous Stem Cell Transplant in 716 Patients With Multiple Myeloma: Low Treatment-Related Mortality, Feasibility of Outpatient Transplant, and Effect of a Multidisciplinary Quality Initiative. <i>Mayo Clinic Proceedings</i> , 2008, 83, 1131-1135. | 1.4 | 90 |
| 318 | Stem cell transplant for chronic lymphocytic leukemia/small lymphocytic lymphoma. <i>Leukemia and Lymphoma</i> , 2008, 49, 835-836. | 0.6 | 0 |
| 319 | Long-term outcome of allogeneic stem cell transplantation in chronic lymphocytic leukemia: analysis after a minimum follow-up of 5 years. <i>Leukemia and Lymphoma</i> , 2008, 49, 1724-1730. | 0.6 | 20 |
| 320 | Allogeneic hematopoietic cell transplantation in myelofibrosis with myeloid metaplasia. <i>Current Hematologic Malignancy Reports</i> , 2007, 2, 34-42. | 1.2 | 1 |
| 321 | Engraftment Syndrome Is Common in Patients with POEMS Syndrome Undergoing PBSCT.. <i>Blood</i> , 2007, 110, 2995-2995. | 0.6 | 0 |
| 322 | Allogeneic stem cell transplantation and donor lymphocyte infusions for chronic myelomonocytic leukemia. <i>Bone Marrow Transplantation</i> , 2006, 37, 1003-1008. | 1.3 | 66 |
| 323 | MPLW515L/K and JAK2V617F Mutations: Single Colony Studies, Lineage Restriction, and Chronology of Clonal Emergence.. <i>Blood</i> , 2006, 108, 116-116. | 0.6 | 6 |
| 324 | Implications of Body Weight Calculations for Autologous Peripheral Blood Stem Cell Transplantation.. <i>Blood</i> , 2006, 108, 5445-5445. | 0.6 | 0 |

| # | ARTICLE | IF | CITATIONS |
|-----|--|-----|-----------|
| 325 | The Increasing Relevance of Copper Deficiency in Hematological Practice.. Blood, 2005, 106, 1679-1679. | 0.6 | 4 |
| 326 | Long Term Follow up of Allogeneic Hematopoietic Stem Cell Transplantation (ASCT) in Chronic Lymphocytic Leukemia (CLL).. Blood, 2005, 106, 5420-5420. | 0.6 | 0 |
| 327 | Autologous Stem Cell Transplantation for Multiple Myeloma in Patients over 70 Years: A Matched Comparison with Patients under 65 Years.. Blood, 2005, 106, 1173-1173. | 0.6 | 1 |
| 328 | Hematopathological Findings in Patients with Copper Deficiency and Hematologic Manifestations.. Blood, 2005, 106, 1680-1680. | 0.6 | 0 |
| 329 | Allogeneic Stem Cell Transplantation (ASCT) and Donor Lymphocyte Infusions (DLI) in the Management of Chronic Myelomonocytic Leukemia (CMML).. Blood, 2005, 106, 5422-5422. | 0.6 | 0 |
| 330 | Use of cyclosporine in hematopoietic cell transplantation. Transplantation Proceedings, 2004, 36, S367-S371. | 0.3 | 21 |
| 331 | A Phase II Study of CC-5013 Treatment for Myelofibrosis with Myeloid Metaplasia: A Preliminary Report.. Blood, 2004, 104, 1505-1505. | 0.6 | 3 |
| 332 | Time Interval from Last Chemotherapy to Stem Cell Collection Correlates with Peripheral Blood Absolute Lymphocyte Count at Apheresis and Survival Post-Autologous Stem Cell Transplantation in Non-Hodgkin's Lymphoma.. Blood, 2004, 104, 2927-2927. | 0.6 | 1 |
| 333 | Increasing the Number of Apheresis Collections Increases Lymphocyte Collection and Affects Survival after Autologous Stem Cell Transplantation for Non-Hodgkin Lymphoma.. Blood, 2004, 104, 892-892. | 0.6 | 2 |
| 334 | Allogeneic Stem Cell Transplantation (SCT) in Untreated First Relapse or Following Re-Induction Chemotherapy for Patients with Acute Myeloid Leukemia (AML).. Blood, 2004, 104, 5143-5143. | 0.6 | 0 |
| 335 | Neutropenic Colitis After Treatment of Acute Myelogenous Leukemia With Idarubicin and Cytosine Arabinoside. Mayo Clinic Proceedings, 2002, 77, 760-762. | 1.4 | 32 |
| 336 | Successful treatment of POEMS syndrome with autologous hematopoietic progenitor cell transplantation. Bone Marrow Transplantation, 2001, 28, 305-309. | 1.3 | 67 |
| 337 | Fulminant Hepatic Failure Secondary to Adenovirus Following Fludarabine-Based Chemotherapy for Non-Hodgkin's Lymphoma. Leukemia and Lymphoma, 2001, 42, 1145-1150. | 0.6 | 7 |
| 338 | Prognostic Relevance of Monosomy at the 13q14 Locus Detected by Fluorescence In Situ Hybridization in B-Cell Chronic Lymphocytic Leukemia. Cancer Genetics and Cytogenetics, 1999, 110, 77-81. | 1.0 | 14 |